Opioids are a class of medications that are regularly endorsed for their pain relieving, or pain-killing, properties it is chronic and non-cancer pain. A typical symptom connected with the utilization of these medications are that they decrease the gastrointestinal tract's motility, making solid discharges and making patients strain. In addition, prolonged utilization of opioids can prompt the harm of sensory system that causes body cells to quit creating endogenous opioids, for example, endorphins. There is high risk of constipation in adults since they have poor diet, poor fluid intake and immobility. The typical symptoms for opioid-induced constipation are feeling lethargic, hard and dry stools, distention and bulged abdomen, painful defecation and loss of appetite. The opioid-induced constipation (OIC) treatment market is an exceptionally alluring and promising market because of the expanding base of opioid-induced constipation OIC sufferers. The report focuses on the Opioid-Induced Constipation (OIC) Treatment market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Opioid-Induced Constipation (OIC) Treatment market. Major Players in the Opioid-Induced Constipation (OIC) Treatment market are: Cubist Pharmaceuticals Takeda Pharmaceutical Company Limited AstraZeneca plc, Inc. GlaxoSmithKline, Inc. Salix Pharmaceuticals, Inc. AIKO Biotechnology S.L.A. Pharma AG Pfizer, Inc. On the basis of types, the Opioid-Induced Constipation (OIC) Treatment market is primarily split into: Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA) Non-selective opioid antagonist μ-Opioid antagonist Locally Acting Chloride Channel Activator (LACCA) On the basis of applications, the market covers: Drug store Independent Pharmacies Hospital Pharmacies Major Regions or countries covered in this report: United States Europe China Japan India Southeast Asia Latin America Middle East and Africa Others Years considered for this report: Historical Years: 2017-2021 Base Year: 2021 Estimated Year: 2022 Forecast Period: 2022-2029
Table of Content 1 Opioid-Induced Constipation (OIC) Treatment Market Overview 1.1 Product Overview and Scope of Opioid-Induced Constipation (OIC) Treatment Market 1.2 Opioid-Induced Constipation (OIC) Treatment Market Segment by Type 1.2.1 Global Opioid-Induced Constipation (OIC) Treatment Market Sales and CAGR (%) Comparison by Type (2017-2029) 1.3 Global Opioid-Induced Constipation (OIC) Treat
